Company intelligence / Profile preview

MRace

Giessen, Hesse, Germany

Ownership: Private
Development stage: Other

Overview

MRace is a biotechnology company focused on the development of highly sensitive diagnostic tools for the detection of cancer-specific mutations. The company utilizes its proprietary M-RACE (Mutation-specific RNA-based Amplification of cDNA Ends) technology to identify and quantify rare genetic alterations in patient samples. This platform is designed to improve the accuracy of liquid biopsies and support personalized medicine by enabling earlier detection and better monitoring of treatment response. MRace aims to provide clinicians with actionable insights to optimize therapeutic strategies for oncology patients.

Therapeutic areas: Oncology
Modalities: DiagnosticBiologic
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on MRace.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRace.

Explore the full profile